Top Section
Explore Business Standard
Don’t miss the latest developments in business and finance.
The acquisition is expected to be completed before March 7, 2025, subject to approval from the Ontario Superior Court of Justice
PAG had earlier acquired Manjushree Technopack for $1bn
These granules, available in 25 mg, 50 mg, and 75 mg per unit dose packets, are a generic equivalent of Kalydeco Oral Granules
Lupin, headquartered in Mumbai, India, is a global pharmaceutical player with products distributed in over 100 markets
These systems can be deployed across various industries ranging from pharmaceuticals, and consumer goods to the automotive sector
Among other demands is the removal of Section 194R, related to marketing samples, which would ease business operations
Krishan Kumar Aurora, chairman emeritus of Pharmed Limited and BioPlus Group, passed away on December 23 at 88. He began his career in 1961 with Smith Kline & French, rising to VP for Southeast Asia
According to Bloomberg, 30 of 41 analysts are bullish on Sun Pharma, while the remaining seven have a neutral rating and only 4 are bearish
Brokerages slash target price after subdued Q2 show
Move comes after drug regulator had suspended nod granted to firm to manufacture, sell PresVu eye drops
The sector is expected to benefit from steady cash flows and low financial leverage, which will help maintain stable credit profiles, even as pharma cos pursue acquisitions in niche therapeutic areas
Akums Drugs and Pharmaceuticals on Friday said it has received patent for a formulation for Sickle Cell Disease (SCD). The company has received a patent from India patent office for its room temperature stable oral suspension of Hydroxyurea, a formulation aimed at managing SCD. "Our constant endeavor is to work on affordable medicines for Orphan Drugs and reduce dependency on imported medicines ensuring patient safety from rare diseases with timely and necessary treatment," Akums Managing Director Sanjeev Jain said in a statement. SCD, a genetic blood disorder, leads to severe health complications such as anaemia, frequent pain episodes and other debilitating symptoms, affecting millions worldwide, especially in India and Africa. Akums said its formulation will come at a fraction of the cost of imported Hydroxyurea solution.
The drug formulations market in India is expected to grow at a CAGR of 9-10 per cent over the next decade with Jan Aushadhi outlets anticipated to emerge as a much stronger player in the country, according to Glenmark Pharmaceuticals. The domestic formulations market is estimated to be at Rs 2 lakh crore, with a growth rate of 11 per cent over the past two decades. "It is projected that the domestic formulations market will maintain a compound annual growth rate (CAGR) of 9-10 per cent over the next decade," the Mumbai-based drug maker said in its Annual Report for 2023-24. As the Trade Generics and Jan Aushadhi channels expand, it is anticipated that these channels could collectively contribute 30 per cent to the market volume in ten years, it stated. The Jan Aushadhi initiative aims to enhance access to cost-effective, unbranded generics by scaling up to 25,000 franchise pharmacies by 2026, it said. "It is estimated that Jan Aushadhi procurement could account for 3-5 per cent o
The company further mentioned that the opinions and claims printed in news stories do not represent Entod Pharmaceuticals
Shares of Shilpa Medicare were trading at Rs 733.15, up by nearly Rs 36, or 5.15 per cent on the BSE. In contrast, the 30-stock BSE Sensex was trading at 81,714 levels, up 0.77 per cent.
Neffy's approval is based on 4 studies in 175 healthy adults without anaphylaxis that measured epinephrine concentrations in blood following administration of neffy
GSK Pharma's stocks were up by 2.49 per cent, ending the day's trade at Rs 2,824.45 apiece on the Bombay Stock Exchange (BSE)
Pharmaceutical industry is urging government to halt the transfer of nutraceutical oversight from FSSAI to the drug regulatory authority, citing potential market impact
Indian pharmaceutical companies recently came under the scanner after global supplies of certain medicines were found to be toxic